
Insights Into HER2+ Breast Cancer
Perspectives on current treatment practices regarding HER2+ metastatic breast cancer, management of progressive HER2+ metastatic disease, and attitudes toward recently introduced and upcoming agents.

Faculty Chair
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US
REPORT SNAPSHOT
Initial Treatment of HER2-Positive Advanced Breast Cancer
- Overview of current data
- Initial therapy
- Impact of prior adjuvant therapy, disease-free interval, disease and patient characteristics
- Is dual HER2 blockade the standard?
- Which HER2-targeted agents?
- Which chemotherapy partner?
- Initial therapy
Management of Progressive HER2-Positive Metastatic Disease
- Overview of current data
- Treatment of progressive disease
- Newer agents (approved and in development)
- Trastuzumab deruxtecan
- T-DM1
- Tucatinib
- Neratinib
- Management of emerging safety issues with HER2-directed therapies (pneumonitis, diarrhea, and interstitial lung disease)
- Evolving guidelines for monitoring brain metastases
- Newer agents (approved and in development)
- Treatment of progressive disease
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held October 14, 2020
- The group of advisors comprised 9 community oncologists
- Data collection was accomplished through use of audience response system questioning and moderated discussion